ND0701

a novel, stable, and less acidic formulation of apomorphine designed to overcome the complex usability and local site reactions observed with other apomorphine formulations for treating Parkinson’s disease (PD)

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Nemas, Mara: 1 article (01/2017)
2.	Nyska, Abraham: 1 article (01/2017)
3.	Ramot, Yuval: 1 article (01/2017)
4.	Rubinski, Anna: 1 article (01/2017)
5.	Schiffenbauer, Yael S: 1 article (01/2017)
6.	Shaltiel-Karyo, Ronit: 1 article (01/2017)
7.	Tsarfati, Yonit: 1 article (01/2017)
8.	Weinstock, Irena: 1 article (01/2017)
9.	Yacoby-Zeevi, Oron: 1 article (01/2017)
10.	Zawoznik, Eduardo: 1 article (01/2017)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/2017 - "Here, in vivo and ex vivo MRI evaluations were used in addition to classical histopathology to assess the infusion site reaction to ND0701, a novel formulation of apomorphine base developed for the treatment of Parkinson's disease, in comparison to the commercial apomorphine hydrochloride (HCl) formulation. "
2.	Necrosis 01/01/2017 - "Histopathological evaluation of ND0701 revealed only minimal inflammation at the sites of infusion, whereas the commercial apomorphine HCl caused persistent inflammatory reactions and necrosis. "
3.	Inflammation (Inflammations) 01/01/2017 - "Histopathological evaluation of ND0701 revealed only minimal inflammation at the sites of infusion, whereas the commercial apomorphine HCl caused persistent inflammatory reactions and necrosis. "
4.	Injection Site Reaction 01/01/2017 - "Here, in vivo and ex vivo MRI evaluations were used in addition to classical histopathology to assess the infusion site reaction to ND0701, a novel formulation of apomorphine base developed for the treatment of Parkinson's disease, in comparison to the commercial apomorphine hydrochloride (HCl) formulation. "

Related Drugs and Biologics

1.	Apomorphine